Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET –SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc.
TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, ...
If you haven’t done so already, we encourage you to determine your short- and long-term career goals to identify your postdoc training needs. Creating an IDP is a great way to do this, and when you’re ...
Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE -- Zenas acquired the ...
Daura Gold Corp. (TSXV: DGC) (“Daura” or the “Company”) is pleased to announce the commencement of Induced Polarization ...
Vaxcyte aims to revolutionize the pneumococcal vaccine market with VAX-31. Click here to read an analysis of PCVX stock now.
Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA ...
Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and ...
Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.
Western Kentucky University’s Board of Regents on Thursday unanimously approved a roughly $5.8 million predevelopment agreement for a widely recognized development firm to undertake design and finance ...
Cellectis SA (CLLS) downgraded after 150% surge—discover valuation concerns, key risks, and what investors should watch ...
Three directors purchased a total of 179,737 shares and 179,737 warrants with an average purchase price of $1.224. Dr. Smith has invested in all of MAIA’s funding rounds since the Company’s inception ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback